Sirna Establishes Broad Product Pipeline in RNAi

Sirna Therapeutics is advancing six major programs in its broadly diversified, clinical-stage product pipeline.

Sirna's pipeline demonstrates the vast opportunity of short interfering RNAs (siRNAs) in systemic, local and topical delivery, enabling the company to address serious unmet medical needs (Huntington's Disease), major disease markets (asthma and diabetes) and novel commercial programs (hair removal).

Key programs are also focused on age-related macular degeneration, Sirna's first program to enter Phase I clinical testing, and oncology, through a collaboration with Eli Lilly.